{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:53:06Z","timestamp":1782208386394,"version":"3.54.5"},"reference-count":23,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Medicine and Pharmacy Carol Davila"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Human papillomavirus (HPV) infection remains the principal etiological factor in cervical cancer development worldwide, with Eastern Europe continuing to demonstrate disproportionately high cervical cancer incidence and mortality rates. Regional disparities in screening implementation, vaccination coverage, and HPV genotype distribution contribute substantially to the persistent burden of HPV-related disease. In recent years, increasing attention has focused on molecular biomarkers and the vaginal microbiome as complementary approaches for improving cervical cancer prevention strategies. This systematic review aimed to evaluate recent evidence regarding HPV genotype distribution, molecular biomarkers, vaginal microbiome composition, and their implications for cervical cancer prevention in Eastern Europe. A systematic literature search was conducted in PubMed\/MEDLINE, Scopus, Web of Science, Embase, and the Cochrane Library for studies published between January 2020 and May 2026. This systematic review was conducted in accordance with the PRISMA 2020 guidelines and prospectively registered in PROSPERO (CRD420261391136). Studies from Eastern European populations reporting data on HPV genotype distribution, screening strategies, vaccination, molecular biomarkers, or vaginal microbiome composition were included. HPV prevalence in screening populations ranged from approximately 12% to over 20%, with HPV16 consistently identified as the predominant genotype across all included studies. However, non-16\/18 high-risk genotypes, particularly HPV31, HPV51, HPV52, HPV66, and HPV68, represented a substantial proportion of infections in several Eastern European cohorts. Studies evaluating CINtec PLUS cytology and HPV E6\/E7 mRNA testing demonstrated improved specificity for identifying clinically significant cervical lesions compared with HPV DNA testing alone. Emerging evidence also suggested associations between vaginal dysbiosis, increased microbial diversity, persistent high-risk HPV infection, and progression to cervical intraepithelial neoplasia. Although the 9-valent HPV vaccine provides coverage for most circulating high-risk genotypes identified in the region, vaccination uptake remains inconsistent throughout Eastern Europe. The findings of this systematic review support the growing importance of extended HPV genotyping, molecular biomarkers, and microbiome-related approaches in cervical cancer prevention strategies in Eastern Europe. Strengthening organized screening programs, expanding vaccination coverage, and improving access to molecular diagnostic technologies remain essential priorities for reducing the regional burden of HPV-related disease.<\/jats:p>","DOI":"10.3390\/life16061039","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:13:37Z","timestamp":1782195217000},"page":"1039","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond HPV in Eastern Europe: Genotype Distribution, Molecular Biomarkers, Vaginal Microbiome, and Implications for Cervical Cancer Prevention"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5847-3977","authenticated-orcid":false,"given":"Eugenia-Alina","family":"Radu","sequence":"first","affiliation":[{"name":"County Clinical Emergency Hospital \u201cSf. Ap. Andrei\u201d, 900591 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8818-9539","authenticated-orcid":false,"given":"Corina-Ioana","family":"Anton","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, Bulevardul Eroii Sanitari 8, 050474 Bucharest, Romania"},{"name":"Department of Medico-Surgical and Prophylactic Disciplines, Titu Maiorescu University, 040441 Bucharest, Romania"},{"name":"Department of Infectious Diseases, \u201cDr. Carol Davila\u201d Central Military Emergency University Hospital, Calea Plevnei 134, 010242 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2508-2551","authenticated-orcid":false,"given":"Cristian-Sorin","family":"Sima","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, Bulevardul Eroii Sanitari 8, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Streinu-Cercel","sequence":"additional","affiliation":[{"name":"Faculty of General Medicine, Carol Davila University of Medicine and Pharmacy, Bulevardul Eroii Sanitari 8, 050474 Bucharest, Romania"},{"name":"Department of Infectious Diseases I, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"National Institute for Infectious Diseases \u201cProf. Dr. Matei Bal\u015f\u201d, Strada Doctor Calistrat Grozovici 1, 021105 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kaliterna, V., Me\u0161trovi\u0107, T., \u010cori\u0107-Mesari\u0107, M., and Bo\u017ei\u010devi\u0107, I. (2025). Genotype-Specific Distribution of High-Risk Human Papillomavirus (HPV) and Microbial Co-Detections in HPV-Positive Women from Southern Croatia. Biomedicines, 13.","DOI":"10.3390\/biomedicines13092100"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100293","DOI":"10.1016\/j.eclinm.2020.100293","article-title":"A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs","volume":"22","author":"Demarco","year":"2020","journal-title":"eClinicalMedicine"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tsakogiannis, D., Zografos, E., Tzioga, L., Zografos, C.G., Zagouri, F., and Bletsa, G. (2025). Prevalence and Genotype Distribution of High-Risk HPV Genotypes Among Women in Greece: A Retrospective Analysis of 3500 Women. Cancers, 17.","DOI":"10.3390\/cancers17081267"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Stasulane, A., Grundmane, J., Sulte, K., Stasulans, J., Cernavska, S., and Smite, L. (2025). Prevalence of human papillomavirus genotypes in Latvia among women participating in cervical cancer screening. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1584677"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wojtyla, C., Ciebiera, M., Kowalczyk, D., and Panek, G. (2020). Cervical cancer mortality in east-central european countries. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17134639"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lasi\u010d, M., O\u0161trbenk, A., Smrkolj, \u0160., Bohinc, K.B., Pflaum, A., and Poljak, M. (2025). Prevalence of High-Risk Human Papillomaviruses (HPV) in Slovenian Women Attending Organized National Cervical Cancer Screening 14 Years After Implementation of the National HPV Vaccination Program. Vaccines, 13.","DOI":"10.3390\/vaccines13101050"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/14760584.2024.2402535","article-title":"Estimating the time required to reach HPV vaccination targets across Europe","volume":"24","author":"Gountas","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/eurpub\/ckae075","article-title":"Understanding the high-risk human papillomavirus prevalence and associated factors in the European country with a high incidence of cervical cancer","volume":"34","author":"Berza","year":"2024","journal-title":"Eur. J. Public Health"},{"key":"ref_9","first-page":"e69173","article-title":"CINtec PLUS: A Novel Alternative Screening Method for Detecting High-Risk Cervical Lesions in Romania","volume":"16","author":"Camarasan","year":"2024","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41416-021-01539-y","article-title":"The use of biomarkers and HPV genotyping to improve diagnostic accuracy in women with a transformation zone type 3","volume":"126","author":"Manley","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J. Low. Genit. Tract. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1002\/cam4.3399","article-title":"Implementation of p16\/Ki67 dual stain cytology in a Danish routine screening laboratory: Importance of adequate training and experience","volume":"9","author":"Hammer","year":"2020","journal-title":"Cancer Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/ijc.33858","article-title":"Accuracy of different triage strategies for human papillomavirus positivity in an Italian screening population","volume":"150","author":"Gustinucci","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1111\/1471-0528.17200","article-title":"Cervical intraepithelial neoplasia in women with transformation zone type 3: Cervical biopsy versus large loop excision","volume":"129","author":"Gustafson","year":"2022","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Br\u0103ila, A.D., Poalelungi, C.V., Albu, C.C., Damian, C.M., D\u020br\u0103, L.M., B\u0103n\u0103\u021beanu, A.M., and Bogdan-Andreescu, C.F. (2025). The Relationship Between Cervicovaginal Infection, Human Papillomavirus Infection and Cervical Intraepithelial Neoplasia in Romanian Women. Diseases, 13.","DOI":"10.3390\/diseases13010018"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Munteanu, I.V., Socolov, D., Socolov, R., Adam, A.M., Adam, G., Vasilache, I.A., Vicoveanu, P., Harabor, V., Harabor, A., and Calin, A.M. (2025). Clinical and Virological Profiles Associated with CINTEC\u00ae PLUS Positivity: A Data-Driven Clustering and Modeling Study. Diagnostics, 15.","DOI":"10.3390\/diagnostics15172200"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ussai, S., Seyidov, T., and Khomasuridze, T. (2025). UNFPA EECA SRH Focal Points; On Behalf Of the Regional Alliance Group Of Experts On Hpv Vaccination. Regional Alliance for Cervical Cancer Prevention in Eastern Europe and Central Asia: Progressing Towards the Target 1 of the Global Strategy for Cervical Cancer Elimination. Healthcare, 13.","DOI":"10.3390\/healthcare13101209"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/LGT.0000000000000802","article-title":"Recommendations for Use of p16\/Ki67 Dual Stain for Management of Individuals Testing Positive for Human Papillomavirus","volume":"28","author":"Clarke","year":"2024","journal-title":"J. Low. Genit. Tract. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(20)30674-4","article-title":"Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: A population-based study","volume":"22","author":"Ryzhov","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1016\/S2468-2667(20)30122-5","article-title":"Tackling cervical cancer in Europe amidst the COVID-19 pandemic","volume":"5","author":"Arbyn","year":"2020","journal-title":"Lancet Public Health"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100436","DOI":"10.1016\/j.jcpo.2023.100436","article-title":"Breast and cervical cancer screening practices in nine countries of Eastern Europe and Central Asia: A population-based survey","volume":"38","author":"Znaor","year":"2023","journal-title":"J. Cancer Polic."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000542504","article-title":"p16INK4a\/Ki67 Dual-Staining Immunocytochemistry to Refer Women Infected by High-Risk Human Papillomavirus for Colposcopy","volume":"69","year":"2025","journal-title":"Acta Cytol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1016\/S2214-109X(22)00241-8","article-title":"Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: A review and synthetic analysis","volume":"10","author":"Bruni","year":"2022","journal-title":"Lancet Glob. Health"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/1039\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:35:49Z","timestamp":1782207349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/6\/1039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["life16061039"],"URL":"https:\/\/doi.org\/10.3390\/life16061039","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}